ArticleClinical rheumatology2026
Urinary phytoestrogen metabolites are associated with a reduced risk of hyperuricemia.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the relationship between individual urinary phytoestrogen metabolites and hyperuricemia (HUA), as well as the potential impact of a mixture of these metabolites on HUA.
methodsThis cross-sectional study included a total of 9253 participants, with data sourced from the National Health and Nutrition Examination Survey (NHANES). Urinary levels of daidzein, o-desmethylangolensin (O-DMA), equol, genistein, enterodiol, and enterolactone were measured to assess exposure to urinary phytoestrogen metabolites. HUA was defined as the study outcome. First, weighted logistic regression and smoothed curve fitting were used to analyze the relationships between individual urinary phytoestrogen metabolites and HUA. Subsequently, weighted quantile sum (WQS) regression, quantile g-computation (qgcomp), and Bayesian kernel machine regression (BKMR) models were used to explore the comprehensive effects of the six phytoestrogen metabolites on HUA.
resultsThe prevalence of HUA in this study was approximately 18.33%. Weighted logistic regression analysis indicated that urinary daidzein, O-DMA, equol, and enterolactone were associated with a reduced risk of HUA. The study further identified threshold effects of daidzein, O-DMA, and equol on the risk of HUA. WQS, qgcomp, and BKMR models revealed that mixed metabolites of urinary phytoestrogens were negatively correlated with HUA risk, with equol and enterolactone being the main contributors. A comprehensive comparison of the results from these models demonstrated high stability and consistency.
conclusionMixed urinary phytoestrogen metabolites were inversely associated with the risk of HUA, with equol and enterolactone serving as the primary contributing factors. This observational study provides a basis for public health strategies but cannot establish causality. Key Points • Large-scale population studies have shown that plant estrogen metabolites (daidzein, o-desmethylangolensin, equol, and enterolactone) are significantly inversely associated with hyperuricemia (HUA) risk. Saturation effects were observed for daidzein, o-desmethylangolensin, and equol. • This study confirms that mixed exposure to these metabolites reduces HUA risk, mainly due to equol and enterolactone. • Promoting public health policies to harness plant estrogens' benefits could improve population health.
Indexed as
Identifiers
41533223What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.